Aggressive or moderate drug therapy for infectious diseases?

Jérémie Sciré, Nathanaël Hozé*, Hildegard Uecker*

* equal contribution

Infectious diseases: Resistance dynamics at two levels

Within-host

Resistance can evolve within any one patient during treatment.

between-host

Resistant pathogen can get transmitted in the community.

The drug dose affects pathogen replication.

consequences for the disease dynamics in the population

The drug dose may be modulated to influence the evolutionary dynamics at both scales. This may be exploited to manage resistance.

The effect is particularly strong for low $R_0$.

Are there trade-offs between the individual and the population levels?

Within-host evolution of resistance

Opposing forces:
- low doses: high abundance of sensitive pathogens triggers strong immune response
- high doses: drug substantially reduces growth even of the resistant strain

Spread of an existing resistant strain

Opposing forces:
- low doses: strong competition with the sensitive strain for susceptible hosts
- high doses: short period of infectiousness even for the resistant strain

Transmission of the resistant strain

Two factors:
- spread of the resistant strain once emerged
- de novo development of resistance across all patients ($\approx$ number of sensitive infections)

$\Rightarrow$ peak shifts with the transmission coefficient $\beta$ ($\approx R_0$)

The dose that minimizes the within-host probability of resistance within the therapeutic window may maximize transmission of the resistant strain in the community.

Quantitative model

Sketch of the within-host dynamics

Sketch of the between-host dynamics

Outbreak probability

If initially a single individual is infected, there are two possible outcomes: (1) early extinction of the epidemic after few infection events (2) a large outbreak with many infected hosts.

A higher dose leads to a lower outbreak probability.

Disease burden

$= \text{total number of days that members of the population suffer from symptoms}$

Competition with the sensitive strain for susceptible hosts spread of resistance. With increasing dose, competitive release allows its spread, unless $R_0$ is large. For very high doses, both strains are equally affected by the drug.

Discussion

Summary, Limitations & Conclusion

The best dose choice depends on whether the main goal is to rapidly increase individual patients' health, to reduce morbidity at the population level (burden), to limit the outbreak probability, or to reduce resistance emergence at the individual or the population levels. What is more, there can be trade-offs between achieving treatment goals at the within-host and between-host levels.

Limitations of the model:

- no mortality; no immuno-compromised patients; no danger of under- or overdosing for individual patients; . . .

Conclusion:

Deciding on a drug dose based on within-host considerations alone may be insufficient for resistance and disease management.

Acknowledgments:

We thank J. Buskeheuer, R. Regis, J. Hermisson, P. Pearsons, A. Thoemen for helpful discussions and the European Research Council and the Swiss National Science Foundation for funding.

Literature:

- T. Sciré et al., submitted
- Read et al., PNAS 2011
- H. Uecker et al., EMBO Rep. 2010

Swiss National Science Foundation for funding.